Authors: Gregory Russell-Jones.
In an attempt to rapidly control of the unprecedented effects of the COVID-19 pandemic, a series of vaccination programmes were rapidly rolled out across the world, with a paucity of studies on their side-effects or efficacy. Lack of testing may be the reason for why there have been an increasing number of reports of new-onset autoimmune phenomena following COVID-19 vaccination. These conditions include immune thrombotic thrombocytopenia, autoimmune liver diseases, Guillain-Barré syndrome, IgA nephropathy, rheumatoid arthritis and systemic lupus erythematosus). It has been postulated that production of autoantibodies may have been due the use of certain vaccine adjuvants such as PEG, used by Pfizer [1]. These side-effects are somewhat more serious than the systemic side effects seen following 2 injections of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccine (58.75%), or BNT162b2 (68.5%) [2]. We report evidence of an extensive and prolonged inflammatory response to a combination of 2 injections of ChAdOx1 nCoV-19, followed by 1 injection of BNT162b2, which subsequently lead to the development of irreversible eye damage typical of Pseudoexfoliation syndrome, in a 71 year old man, of excellent health with no predisposing sequelae apart from his age.
View/Download pdf